- Home
- Equipment
- usa california
- clinical trial
Refine by
Clinical Trial Equipment Supplied In Usa California
95 equipment items found
Manufactured by:T-Knife GmbH based inBerlin, GERMANY
TK-8001 is a CD8 TCR-T specific for the Melanoma-associated Antigen Gene-A1, or MAGE-A1. MAGE-A1 is associated with hallmarks of aggressive cancers and poor clinical prognosis, and there is an emerging body of evidence indicating its involvement as a potential driver of tumorigenesis. MAGE-A1 represents an attractive therapeutic target given the high unmet need in MAGE-A1 expressing cancers, no ...
Manufactured by:Neofect based inWatertown, MASSACHUSETTS (USA)
The Neofect Smart Glove was designed with neuroplasticity in mind. Training programs promote motor learning and brain reorganization to improve arm and hand function for adults rehabilitating from stroke. Sensor technology detects and records movement data. Neofect Smart Glove is a high-tech rehab device that measures movements of the forearm, wrist, and digits with accelerometer and bending ...
by:LIXTE Biotechnology Holdings, Inc. based inPasadena, CALIFORNIA (USA)
Pre-clinical studies showed that LB-100 alone inhibits a spectrum of human cancers but when combined with standard cytotoxic drugs and/or radiation, LB-100 potentiates their effectiveness against hematologic and solid tumor cancers without enhancing toxicity. In addition, given at very low doses in animal models of cancer, LB-100 markedly increased the effectiveness of a PD-1 blocker, one of the ...
Manufactured by:Biocardia, Inc. based inSunnyvale, CALIFORNIA (USA)
The investigational CardiAMP™ Cell Therapy is designed to be a comprehensive biotherapeutic heart failure solution, incorporating: a proprietary molecular diagnostic to characterize the potency of a patient’s own bone marrow cells and determine if they are an optimal candidate for therapy. a point of care processing platform to prepare cells at the patient’s bedside. an ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
The IND for CX-188 was cleared by the FDA. Following a program and portfolio prioritization, CytomX has decided to indefinitely postpone the clinical trials of CX-188, a PD-1 Probody. CytomX may elect to initiate clinical trials of CX-188 in the future. ...
Manufactured by:ClearPoint Neuro, Inc. based inIrvine, CALIFORNIA (USA)
When combined with the SmartFlow® Cannula*, this can allow for assessment of infusion coverage and delivery of approved therapeutics to regions of interest in the brain in clinical ...
Manufactured by:Perspectum based inOxford, UNITED KINGDOM
We partner with ProPath to combine best-in class imaging with best-in-class pathology into a single integrated workflow for more objective, quantitative biopsy data. Our digital pathology service streamlines and improves decision-making in clinical trials with expert central review and easily accessible reports with quick turnaround ...
by:Evofem Biosciences, Inc. based inSan Diego, CALIFORNIA (USA)
This collaboration will focus on determining compatibility and stability of OB-002 in Phexxi and is expected to yield results in the third quarter of 2022. Assuming positive results, the Company and Orion will seek government and philanthropic funding for subsequent clinical trials of the MPT vaginal gel product candidate. ...
Manufactured by:INOVIO Pharmaceuticals based inPlymouth Meeting, PENNSYLVANIA (USA)
INOVIO has employed its CELLECTRA®2000 smart delivery device for over a decade in more than 40 oncology and infectious disease clinical trials, including those for COVID-19 disease. For intramuscular delivery, INOVIO uses its CELLECTRA 5PSP in its Phase 3 clinical trial for VGX-3100. INOVIO is developing its next-generation ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
Bristol Myers Squibb is enrolling patients in the dose escalation phase of a Phase 1/2a clinical trial (NCT03994601) of a second anti-CTLA-4 Probody, BMS-986288, based on a modified version of Yervoy® (ipilimumab), to evaluate a CTLA-4-directed Probody therapeutic alone or in combination with Opdivo® (nivolumab) in patients with selected advanced solid ...
Manufactured by:Addex Therapeutics based inGeneva, SWITZERLAND
Our partner, Janssen Pharmaceuticals, Inc., or Janssen, a subsidiary of Johnson & Johnson is conducting a placebo- controlled Phase 2a proof of concept clinical trial of ADX71149 in epilepsy patients since June 2021. We expect the first part to be completed in the first quarter of 2023. Under our agreement with Janssen, Janssen is responsible for financing ...
Manufactured by:BridgeBio Pharma, Inc. based inPalo Alto, CALIFORNIA (USA)
Infigratinib is an orally administered, ATP-competitive, FGFR1-3 tyrosine kinase inhibitor in development for the treatment of FGFR-driven cancers. Multiple Phase 3 clinical trials are currently enrolling; please explore www.clinicaltrials.gov for more information. TRUSELTIQ™ (infigratinib) obtained accelerated approval by FDA, was conditionally approved by ...
Manufactured by:Immune-Onc Therapeutics, Inc. based inPalo Alto, CALIFORNIA (USA)
FDA has cleared the IND application for IO-108 as a potential therapy for solid tumors. The company expects to begin clinical trials with IO-108 in the second half of ...
Manufactured by:BridgeBio Pharma, Inc. based inPalo Alto, CALIFORNIA (USA)
The disease can also affect the lining of the mouth, esophagus, eye, anus and vagina. BridgeBio completed a Phase 2 clinical trial evaluating safety and tolerability of PTR-01, as well as clinical proof of concept, and has initiated a Phase 2 extension ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
In addition to CD38 targeting in multiple myeloma, targeting of other tumor-associated cell-surface proteins has been clinically investigated. Of these antigens, the TNF-superfamily member B-cell Maturation Antigen (BCMA) is among the most researched. Several clinical trials in multiple myeloma have shown promising initial results targeting BCMA ...
Manufactured by:BridgeBio Pharma, Inc. based inPalo Alto, CALIFORNIA (USA)
In mouse models of achondroplasia, infigratinib demonstrated robust bone growth and clear improvement in cranial and spinal defects. BridgeBio is currently conducting a Phase 2 clinical trial in achondroplasia patients to evaluate the safety and tolerability of low-dose infigratinib, as well as clinical ...
Manufactured by:Elixir Medical Corporation based inMilpitas, CALIFORNIA (USA)
Sirolimus is the most widely known mTOR inhibitor with a well-established safety and effectiveness profile in various treatment applications: Drug-eluting stents, Transplant, Oncology. Novolimus and Sirolimus have been studied as part of Elixir Medical’s Clinical Programs. These clinical trials for DynamX™, DESyne®, ...
Manufactured by:Meissa Vaccines, Inc. based inRedwood City, CALIFORNIA (USA)
Meissa is developing MV-012-968, an intranasal (needle-free), adjuvant-free, live attenuated vaccine candidate, to protect infants and at-risk, older adults from RSV. In Phase 1 clinical trials, Meissa’s RSV vaccine candidate was well-tolerated, heavily attenuated, and stimulated a strong RSV-specific mucosal IgA response in participants (adults and young ...
Manufactured by:Ardigen based inKraków, POLAND
Quick solution for effective immune responses in clinical trials; We have created an Artificial Intelligence platform dedicated to being a part of the therapeutic cancer vaccine development. The ArdImmune Vax platform uses sequencing data to generate and prioritize antigen targets for cancer vaccines and T-cell ...
Manufactured by:Entero Therapeutics, Inc. based inBoca Raton, FLORIDA (USA)
FW-ICI-AC is a niclosamide-based, oral, small molecule anti-inflammatory inhibitor therapy for the treatment of immune checkpoint inhibitor (ICI)-associated colitis and diarrhea in metastatic cancer patients. The PASSPORT clinical trial, a Phase 2a study to determine the safety and potential efficacy of niclosamide in the treatment of ICI-AC, received FDA IND ...